You are here:

Archived: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a full submission

levetiracetam (Keppra®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.

In the pivotal study, there was a significantly greater reduction in the primary generalised tonic-clonic seizure frequency in the levetiracetam group compared with the placebo group. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 396/07
Manufacturer: UCB Pharma Ltd
Indication: as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 10 September 2007

Current Advice

Resubmission 11 February 2008

Back